GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024

PARIS--(BUSINESS WIRE)--Mar 12, 2024--

Related Keywords

United Kingdom ,Paris ,France General ,France ,United States ,American ,Guillaume Van Renterghem ,Gensight Biologics Euronext ,Laurence Rodriguez ,Nancyj Newman ,Ivan Tortet ,Gensight Biologics ,European Medicines Agency ,Emory University School Of Medicine ,Ophthalmology Society ,Early Access Program ,Three New Meta Analyses ,Business Wire ,Sight Biologics ,Leber Hereditary Optic Neuropathy ,North American Neuro Ophthalmology Society ,Leodelle Jolley Professor ,Emory University School ,Relevant Recovery ,Chief Executive Officer ,Sight Biologic ,Mitochondrial Targeting Sequence ,Gensight Biologic ,Hereditary Optic Neuropathy ,Institut De La Vision ,Adeno Associated Virus ,Best Corrected Visual Acuity ,National Business ,